View Future GrowthVeradermics 過去の業績過去 基準チェック /06Veradermicsの収益は年平均-154.3%で減少しているが、Pharmaceuticals業界はgrowingで9.7%年平均の収益となった。主要情報-154.26%収益成長率-150.78%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率n/a株主資本利益率-59.13%ネット・マージンn/a前回の決算情報31 Mar 2026最近の業績更新更新なしすべての更新を表示Recent updatesライブニュース • May 21Veradermics Shows Strong Hair Growth Results and Raises US$767 Million for Lead TreatmentVeradermics reported positive topline Phase 2/3 results for VDPHL01, an extended-release oral minoxidil tablet, showing robust and rapid hair growth with a favorable safety profile in males with pattern hair loss. The company completed enrollment in its pivotal Phase 3 Study 304 for males and is actively enrolling females in Study 306, with additional data readouts expected in the second half of 2026. Veradermics raised about US$766.8 million through an upsized IPO, follow-on offerings, and private placements, and reported a net loss of US$27.2 million in Q1 2026 tied to higher research and development spending. These developments position Veradermics as a focused late-stage clinical company in hair loss treatment, with substantial capital earmarked to fund operations into 2030 and to support ongoing clinical programs. Investors may want to monitor future trial readouts and any regulatory updates, while keeping in mind that the company is still loss-making and dependent on successful clinical and commercial execution for its lead candidate.お知らせ • Apr 30+ 1 more updateVeradermics, Incorporated has completed a Follow-on Equity Offering in the amount of $384.379 million.Veradermics, Incorporated has completed a Follow-on Equity Offering in the amount of $384.379 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,843,790 Price\Range: $100お知らせ • Apr 28Veradermics, Incorporated has filed a Follow-on Equity Offering.Veradermics, Incorporated has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,350,000Seeking Alpha • Apr 28Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline ThesisSummary Veradermics delivered robust Phase 2/3 data for VDPHL01, showing 30–33 hairs/cm² regrowth vs. 7/cm² placebo and placebo-like safety. MANE’s late-stage, oral, extended-release minoxidil targets a large, underserved cash-pay hair loss market, with rapid onset and high patient satisfaction. The current $3.7B market cap reflects high expectations for VDPHL01’s regulatory approval and commercialization as a first-in-class oral therapy. A strong cash position post-offering supports Phase 3 completion; execution on VDPHL01 is central to valuation and future stock momentum. Read the full article on Seeking Alphaお知らせ • Feb 10Veradermics, Incorporated Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair LossVeradermics, Incorporated announced completion of enrollment in its second Phase 3 registration-directed clinical trial evaluating VDPHL01 for the treatment of male pattern hair loss. Following the previously announced completion of enrollment in Veradermics' first Phase 2/3 trial, this milestone marks the completion of enrollment across both Phase 3 clinical trials of VDPHL01 in males, encompassing more than 1,000 participants. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements regarding the timing of completion of and data from the Phase 3 clinical trials for VDPHL01 for thetreatment of male and female pattern hair loss; the release profile of VDPHL01 and whether the release profile will achieve its intended effect; whether Veradermics will successfully file a new drug application for VDPHL01; and the projected size of the market for pattern hair loss treatments. Veradermics' anticipation that its success will depend on the approval and successful commercialization of VDPHL01, which is its lead product candidate, and if Veradermics is unable to obtain regulatory approval for, and successfully commercialize, VDPHL01, or any other current or future product candidates, or experience significant delays in doing so, its business will be materially harm; risks related to preclinical and clinical development and that results of earlier studies and trials may not be predictive of future preclinical studies or clinical trial results; the risk that Veradermics may encounter substantial delays in preclinical and clinical trials, or may not be able to conduct or complete preclinical or clinical trials on the expected timelines, if at all; the risk that the U.S. Food and Drug Administration does not conclude that VDPHL01 satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for VDPHL01 under Section 505(b)(2") are not as Veradermics expects, the approval pathway for those product candidates takes longer or costs more than anticipated; the risk that adverse events or undesirable side effects are caused by Veradermics' product candidates; competition from other companies; risks related to developing Veradermics' sales, marketing and distribution capability; the risk that even if Veradermics obtains regulatory approval for VDPHL01 or any other product candidates, such products may fail to achieve market acceptance; the risk that the commercial opportunity for VDPHL01 or Any other current or future product candidates may be smaller than Veradermics expects; the cash-pay healthcare market for VDPHL01 may limit Veradermics' ability to increase sales or achieve profitability; risks relating to effectively maintaining, promoting and enhancing Veradermics' reputation and VDPHL01 brand recognition in a cost-effective manner; risks related to Veradermics' need to grow its organization; the ability of Veradermics to successfully execute its intellectual property strategy for VDPHL01 and risks related to Veradermic' need to grow its organization. the ability of Veradermic to successfully execute its intellectual property strategies for VDPHL01 and risk related to Veradermics's ability to obtain and maintain sufficient intellectual property protection for VDPHL01 and other current and any future product candidates and other proprietary technologies; risks related to ongoing regulatory obligations for any approved products; risks related to Verader mics' reliance on third parties for the manufacture of drug or biological substances for preclinical studies and clinical trials and expectations that Veradermics will continue to do so for commercialization of any product candidates that are approved for marketing; risks related to VeraderMics' reliance and expected continued reliance on third parties to conduct preclinical studies and clinical trials; global macro conditions; global macro and regulatory obligations for any approved products.お知らせ • Feb 04Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million.Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 15,077,647 Price\Range: $17 Transaction Features: Sponsor Backed Offering収支内訳Veradermics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NYSE:MANE 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 260-98187231 Dec 250-83106230 Sep 250-6264931 Dec 240-27323質の高い収益: MANEは現在利益が出ていません。利益率の向上: MANEは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MANEの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。成長の加速: MANEの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: MANEは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。株主資本利益率高いROE: MANEは現在利益が出ていないため、自己資本利益率 ( -59.13% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 13:17終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Veradermics, Incorporated 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Prakhar AgrawalCantor Fitzgerald & Co.Geoffrey MeachamCitigroup IncRoger SongJefferies LLC1 その他のアナリストを表示
ライブニュース • May 21Veradermics Shows Strong Hair Growth Results and Raises US$767 Million for Lead TreatmentVeradermics reported positive topline Phase 2/3 results for VDPHL01, an extended-release oral minoxidil tablet, showing robust and rapid hair growth with a favorable safety profile in males with pattern hair loss. The company completed enrollment in its pivotal Phase 3 Study 304 for males and is actively enrolling females in Study 306, with additional data readouts expected in the second half of 2026. Veradermics raised about US$766.8 million through an upsized IPO, follow-on offerings, and private placements, and reported a net loss of US$27.2 million in Q1 2026 tied to higher research and development spending. These developments position Veradermics as a focused late-stage clinical company in hair loss treatment, with substantial capital earmarked to fund operations into 2030 and to support ongoing clinical programs. Investors may want to monitor future trial readouts and any regulatory updates, while keeping in mind that the company is still loss-making and dependent on successful clinical and commercial execution for its lead candidate.
お知らせ • Apr 30+ 1 more updateVeradermics, Incorporated has completed a Follow-on Equity Offering in the amount of $384.379 million.Veradermics, Incorporated has completed a Follow-on Equity Offering in the amount of $384.379 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,843,790 Price\Range: $100
お知らせ • Apr 28Veradermics, Incorporated has filed a Follow-on Equity Offering.Veradermics, Incorporated has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 3,350,000
Seeking Alpha • Apr 28Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline ThesisSummary Veradermics delivered robust Phase 2/3 data for VDPHL01, showing 30–33 hairs/cm² regrowth vs. 7/cm² placebo and placebo-like safety. MANE’s late-stage, oral, extended-release minoxidil targets a large, underserved cash-pay hair loss market, with rapid onset and high patient satisfaction. The current $3.7B market cap reflects high expectations for VDPHL01’s regulatory approval and commercialization as a first-in-class oral therapy. A strong cash position post-offering supports Phase 3 completion; execution on VDPHL01 is central to valuation and future stock momentum. Read the full article on Seeking Alpha
お知らせ • Feb 10Veradermics, Incorporated Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair LossVeradermics, Incorporated announced completion of enrollment in its second Phase 3 registration-directed clinical trial evaluating VDPHL01 for the treatment of male pattern hair loss. Following the previously announced completion of enrollment in Veradermics' first Phase 2/3 trial, this milestone marks the completion of enrollment across both Phase 3 clinical trials of VDPHL01 in males, encompassing more than 1,000 participants. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements regarding the timing of completion of and data from the Phase 3 clinical trials for VDPHL01 for thetreatment of male and female pattern hair loss; the release profile of VDPHL01 and whether the release profile will achieve its intended effect; whether Veradermics will successfully file a new drug application for VDPHL01; and the projected size of the market for pattern hair loss treatments. Veradermics' anticipation that its success will depend on the approval and successful commercialization of VDPHL01, which is its lead product candidate, and if Veradermics is unable to obtain regulatory approval for, and successfully commercialize, VDPHL01, or any other current or future product candidates, or experience significant delays in doing so, its business will be materially harm; risks related to preclinical and clinical development and that results of earlier studies and trials may not be predictive of future preclinical studies or clinical trial results; the risk that Veradermics may encounter substantial delays in preclinical and clinical trials, or may not be able to conduct or complete preclinical or clinical trials on the expected timelines, if at all; the risk that the U.S. Food and Drug Administration does not conclude that VDPHL01 satisfies the requirements for the Section 505(b)(2) regulatory approval pathway, or if the requirements for VDPHL01 under Section 505(b)(2") are not as Veradermics expects, the approval pathway for those product candidates takes longer or costs more than anticipated; the risk that adverse events or undesirable side effects are caused by Veradermics' product candidates; competition from other companies; risks related to developing Veradermics' sales, marketing and distribution capability; the risk that even if Veradermics obtains regulatory approval for VDPHL01 or any other product candidates, such products may fail to achieve market acceptance; the risk that the commercial opportunity for VDPHL01 or Any other current or future product candidates may be smaller than Veradermics expects; the cash-pay healthcare market for VDPHL01 may limit Veradermics' ability to increase sales or achieve profitability; risks relating to effectively maintaining, promoting and enhancing Veradermics' reputation and VDPHL01 brand recognition in a cost-effective manner; risks related to Veradermics' need to grow its organization; the ability of Veradermics to successfully execute its intellectual property strategy for VDPHL01 and risks related to Veradermic' need to grow its organization. the ability of Veradermic to successfully execute its intellectual property strategies for VDPHL01 and risk related to Veradermics's ability to obtain and maintain sufficient intellectual property protection for VDPHL01 and other current and any future product candidates and other proprietary technologies; risks related to ongoing regulatory obligations for any approved products; risks related to Verader mics' reliance on third parties for the manufacture of drug or biological substances for preclinical studies and clinical trials and expectations that Veradermics will continue to do so for commercialization of any product candidates that are approved for marketing; risks related to VeraderMics' reliance and expected continued reliance on third parties to conduct preclinical studies and clinical trials; global macro conditions; global macro and regulatory obligations for any approved products.
お知らせ • Feb 04Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million.Veradermics, Incorporated has completed an IPO in the amount of $256.319999 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 15,077,647 Price\Range: $17 Transaction Features: Sponsor Backed Offering